Young child with Doctor

Latest press releases

Friday, 24 October 2014
Lynparza™ (olaparib) receives positive CHMP opinion in the EU for the maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian cancer AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorisation of Lynparza™ (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour DNA repair pathway deficiencies to preferentially kill cancer cells.
Thursday, 16 October 2014
AstraZeneca strengthens partnership with the University of Cambridge AstraZeneca, together with its global biologics research and development arm, MedImmune,  today announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership.
Thursday, 9 October 2014
Positive results from Phase IIb benralizumab study in severe asthma published in The Lancet Respiratory Medicine AstraZeneca today announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell.
Saturday, 27 September 2014
AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid.
Friday, 26 September 2014
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol), an investigational, peripherally-acting mu-opioid receptor antagonist (PAMORA), for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Friday, 26 September 2014
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a Type-II variation update* to the European label for IRESSA® (gefitinib).
Thursday, 25 September 2014
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines AstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.
Friday, 19 September 2014
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes AstraZeneca today announced 28-week results from DURATION-NEO-1
Tuesday, 16 September 2014
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Tuesday, 16 September 2014
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.